Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.41 |
| ▸ | HTR3B | O95264 | 4/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670116 | 0.83 | CASP1 (0.34) | HRH4HRH3ALDH1A1PDE10APARP1 | |
| SCHEMBL16238283 | 0.82 | HTR3E (0.43) | HTR3AHRH4HTR3EHTR3BHTR3D | |
| SCHEMBL17778155 | 0.79 | KMT2A (0.43) | KDM4EALDH1A1PDE10A | |
| SCHEMBL16754643 | 0.79 | KMT2A (0.43) | KDM4EALDH1A1PDE10A | |
| SCHEMBL16775788 | 0.79 | KMT2A (0.43) | KDM4EALDH1A1PDE10A | |
| SCHEMBL16754467 | 0.79 | KMT2A (0.43) | KDM4EALDH1A1PDE10A | |
| SCHEMBL16754674 | 0.79 | KMT2A (0.43) | KDM4EALDH1A1PDE10A | |
| SCHEMBL17778266 | 0.79 | KMT2A (0.43) | KDM4EALDH1A1PDE10A | |
| SCHEMBL17778198 | 0.79 | KMT2A (0.43) | KDM4EALDH1A1PDE10A | |
| SCHEMBL16238309 | 0.78 | PDE10A (0.49) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044338-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | HTR3A 4196/4885HRH4 2796/4885HTR3E 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.